Rating Change
Needham analysts reiterated a Buy rating on NeoGenomics, Inc. (NASDAQ:NEO) on July 29, 2026.
reiterateNASDAQ:NEO
Needham Reiterates Buy Rating on NeoGenomics, Inc. (NEO)
Rating Change Needham analysts reiterated a Buy rating on NeoGenomics, Inc. (NASDAQ:NEO) on July 29, 2026. Market Context NeoGenomics, Inc.
Market Context
NeoGenomics, Inc. operates in the Healthcare sector. The stock currently trades at $15.27 with a market capitalization of $300.9M.
Analyst coverage from Needham provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for NeoGenomics, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for NeoGenomics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 29, 2026 | Needham | Buy | N/A |
| Jul 24, 2026 | Benchmark | Buy | N/A |
| Apr 29, 2026 | TD Cowen | Buy | N/A |
| Apr 29, 2026 | Benchmark | Buy | N/A |
| Apr 29, 2026 | Leerink Partners | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View NEO Stock Page
Frequently Asked Questions
What does a Buy rating mean for NEO?
A Buy rating from Needham reflects the analyst's outlook on NeoGenomics, Inc. (NASDAQ:NEO). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the NEO forecast page.
